Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: Implications for Parkinson's disease

Molecular Neurodegeneration

Volumn 9, Issue 1, 2014, Pages

  Ayton, Scott ^a   Lei, Peng ^a   Adlard, Paul A ^a   Volitakis, Irene ^a   Cherny, Robert A ^a   Bush, Ashley I ^a   Finkelstein, David I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Age; Ceruloplasmin; Iron; Parkinson's disease

Indexed keywords

CERULOPLASMIN; IRON;

AGING; ANIMAL; BRAIN LEVEL; C57BL MOUSE; DEFICIENCY; DEGENERATIVE DISEASE; DISEASE MODEL; GENETICS; IRON METABOLISM DISORDER; KNOCKOUT MOUSE; MOUSE; NERVE CELL; PARKINSONISM; PATHOLOGY; PHYSIOLOGY; SUBSTANTIA NIGRA;

AGING; ANIMALS; BRAIN CHEMISTRY; CERULOPLASMIN; DISEASE MODELS, ANIMAL; IRON; IRON METABOLISM DISORDERS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA;

EID: 84903870684     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-9-27     Document Type: Article

References (26)

1. An iron-dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. Hare DJ, Lei P, Ayton S, Roberts BR, Grimm R, George JL, Bishop D, Beavis A, Donovan SJ, McColl G, Volitakis I, Masters CL, Adlard PA, Cherny RA, Bush AI, Finkelstein DI, Dobel P, Chem Sci 2014 5 2160 2169
2. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D, J Neurochem 2001 76 1766 1773 (Pubitemid 32221116)
3. Increased nigral iron content in postmortem parkinsonian brain. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD, Lancet 1987 2 1219 1220 (Pubitemid 17156630)
4. Ceruloplasmin dysfunction and therapeutic potential for parkinson disease. Ayton S, Lei P, Duce JA, Wong BX, Sedjahtera A, Adlard PA, Bush AI, Finkelstein DI, Ann Neurol 2013 73 554 559
5. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, Wong BX, Adlard PA, Cherny RA, Lam LQ, Roberts BR, Volitakis I, Egan GF, McLean CA, Cappai R, Duce JA, Bush AI, Nat Med 2012 18 291 295
6. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Martin WR, Wieler M, Gee M, Neurology 2008 70 1411 1417 (Pubitemid 351521933)
7. Is r2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. Ulla M, Bonny JM, Ouchchane L, Rieu I, Claise B, Durif F, PLoS ONE 2013 8 57904
8. Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease. Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garcon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonniere B, Strubi-Vuillaume I, Zahr N, Destee A, Corvol JC, Poltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R, Antioxidants Redox Signaling 2014 21 195 210
9. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, Zeiler B, Bornemann A, Pahnke J, Becker G, Riess O, Berg D, Neurology 2004 63 1912 1917 (Pubitemid 39532390)
10. Late onset parkinsonian syndrome in Hallervorden-Spatz disease. Alberca R, Rafel E, Chinchon I, Vadillo J, Navarro A, J Neurol Neurosurg Psychiatry 1987 50 1665 1668 (Pubitemid 18096677)
11. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, Chinnery PF, Coulthard A, Jackson MJ, Jackson AP, McHale DP, Hay D, Barker WA, Markham AF, Bates D, Curtis A, Burn J, Nat Genet 2001 28 350 354 (Pubitemid 32702424)
12. The neurological presentation of ceruloplasmin gene mutations. McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H, Eur Neurol 2008 60 200 205
13. Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease. Bharucha KJ, Friedman JK, Vincent AS, Ross ED, J Neurol 2008 255 1957 1962
14. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Jin L, Wang J, Zhao L, Jin H, Fei G, Zhang Y, Zeng M, Zhong C, Brain 2011 134 50 58
15. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease. Jin L, Wang J, Jin H, Fei G, Zhang Y, Chen W, Zhao L, Zhao N, Sun X, Zeng M, Zhong C, Eur J Neurol 2012 19 969 976
16. Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: a follow-up study. Torsdottir G, Sveinbjornsdottir S, Kristinsson J, Snaedal J, Johannesson T, J Neurol Sci 2006 241 53 58 (Pubitemid 43112516)
17. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C, Neurochem Res 2008 33 1717 1723
18. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Boll MC, Sotelo J, Otero E, Alcaraz-Zubeldia M, Rios C, Neurosci Lett 1999 265 155 158 (Pubitemid 29207389)
19. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. Olivieri S, Conti A, Iannaccone S, Cannistraci CV, Campanella A, Barbariga M, Codazzi F, Pelizzoni I, Magnani G, Pesca M, Franciotta D, Cappa SF, Alessio M, J Neurosci 2011 31 18568 18577
20. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S, J Neurosci 2002 22 6578 6586 (Pubitemid 35386414)
21. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL, Bush AI, Li QX, J Biol Chem 2002 277 44670 44676 (Pubitemid 36159056)
22. Serum iron levels and the risk of Parkinson disease: a mendelian randomization study. Pichler I, Del Greco MF, Gogele M, Lill CM, Bertram L, Do CB, Eriksson N, Foroud T, Myers RH, Nalls M, Keller MF, International Parkinson's Disease Genomics Consortium; Wellcome Trust Case Control Consortium 2, Benyamin B, Whitfield JB, Pramstaller PP, Hicks AA, Thompson JR, Minelli C, PLoS Med 2013 10 1001462
23. Induction of ferroxidase enzymatic activity by copper reduces MPP(+)-evoked neurotoxicity in rats. Rubio-Osornio M, Montes S, Heras-Romero Y, Guevara J, Rubio C, Aguilera P, Rivera-Mancia S, Floriano-Sanchez E, Monroy-Noyola A, Rios C, Neurosci Res 2013 75 250 255
24. Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. Molina-Holgado F, Gaeta A, Francis PT, Williams RJ, Hider RC, J Neurochem 2008 105 2466 2476 (Pubitemid 351782272)
25. Oxidative and nitrative protein modifications in Parkinson's disease. Danielson SR, Andersen JK, Free Radic Biol Med 2008 44 1787 1794
26. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B 3rd, Stockwell BR, Cell 2012 149 1060 1072